Paper39199656
Perioperative Predictive Factors for Tumor Regression and Survival in Non-Small Cell Lung Cancer Patients Undergoing Neoadjuvant Treatment and Lung Resection.
Damirov F and 10 others. Cancers (Basel), 2024. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Perioperative Predictive Factors for Tumor Regression and Survival in Non-Small Cell Lung Cancer Patients Undergoing Neoadjuvant Treatment and Lung Resection. Papers, record 39199656. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39199656
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Perioperative Predictive Factors for Tumor Regression and Survival in Non-Small Cell Lung Cancer Patients Undergoing Neoadjuvant Treatment and Lung Resection.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References42
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34811893 | Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable non-small cell lung cancer. | Asia Pac J Clin Oncol | 2022 | https://conductscience.org/library/papers/34811893 | PubMed |
| 2 | 37903504 | Association between pathologic response and survival after neoadjuvant therapy in lung cancer. | Nat Med | 2024 | https://conductscience.org/library/papers/37903504 | PubMed |
| 3 | 24384493 | Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. | Lancet Oncol | 2014 | https://conductscience.org/library/papers/24384493 | PubMed |
| 4 | 35543472 | Role of fluorodeoxyglucose-positron emission tomography in predicting the pathological response and prognosis after neoadjuvant chemoradiotherapy for locally advanced non-small-cell lung cancer. | Interact Cardiovasc Thorac Surg | 2022 | https://conductscience.org/library/papers/35543472 | PubMed |
| 5 | 21676484 | Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancer. | Lung Cancer | 2011 | https://conductscience.org/library/papers/21676484 | PubMed |
| 6 | 22997251 | Surgery on unfavourable persistent N2/N3 non-small-cell lung cancer after trimodal therapy: do the results justify the risk? | Interact Cardiovasc Thorac Surg | 2012 | https://conductscience.org/library/papers/22997251 | PubMed |
| 7 | 35403841 | Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. | N Engl J Med | 2022 | https://conductscience.org/library/papers/35403841 | PubMed |
| 8 | 25110337 | Differences in patterns of recurrence in early-stage versus locally advanced non-small cell lung cancer. | Ann Thorac Surg | 2014 | https://conductscience.org/library/papers/25110337 | PubMed |
| 9 | 28123901 | Immune contexture and histological response after neoadjuvant chemotherapy predict clinical outcome of lung cancer patients. | Oncoimmunology | 2016 | https://conductscience.org/library/papers/28123901 | PubMed |
| 10 | 27448762 | The IASLC Lung Cancer Staging Project: Methodology and Validation Used in the Development of Proposals for Revision of the Stage Classification of NSCLC in the Forthcoming (Eighth) Edition of the TNM Classification of Lung Cancer. | J Thorac Oncol | 2016 | https://conductscience.org/library/papers/27448762 | PubMed |
| 11 | 26527789 | Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE). | J Clin Oncol | 2015 | https://conductscience.org/library/papers/26527789 | PubMed |
| 12 | 11713138 | Grading of tumor regression in non-small cell lung cancer : morphology and prognosis. | Chest | 2001 | https://conductscience.org/library/papers/11713138 | PubMed |
| 13 | 18721582 | The treatment of patients with stage IIIA non-small cell lung cancer from N2 disease: who returns to the surgical arena and who survives. | Ann Thorac Surg | 2008 | https://conductscience.org/library/papers/18721582 | PubMed |
| 14 | 38090369 | Adjuvant and neo-adjuvant immunotherapy in resectable non-small cell lung cancer (NSCLC): Current status and perspectives. | Cancer Innov | 2023 | https://conductscience.org/library/papers/38090369 | PubMed |
| 15 | 19632716 | Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. | Lancet | 2009 | https://conductscience.org/library/papers/19632716 | PubMed |
| 16 | 9341895 | Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment. | J Cancer Res Clin Oncol | 1997 | https://conductscience.org/library/papers/9341895 | PubMed |
| 17 | 26200453 | Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors. | J Thorac Oncol | 2015 | https://conductscience.org/library/papers/26200453 | PubMed |
| 18 | 26543609 | Clinical outcomes of surgery after induction treatment in patients with pathologically proven N2-positive stage III non-small cell lung cancer. | J Thorac Dis | 2015 | https://conductscience.org/library/papers/26543609 | PubMed |
| 19 | 27987576 | Radiologic-pathologic correlation of response to chemoradiation in resectable locally advanced NSCLC. | Lung Cancer | 2016 | https://conductscience.org/library/papers/27987576 | PubMed |
| 20 | 20100967 | Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study. | J Clin Oncol | 2010 | https://conductscience.org/library/papers/20100967 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39199656
GET https://conductscience.org/api/papers/v1/39199656/references?page=2